Search

Displaying results 1811 - 1820 of 10000 in total
  1. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  2. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy.

  3. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]

  4. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

    Products: LIKMUN-E
  5. Drug

    Pyrantel

    go.drugbank.com/drugs/DB11156
    ApprovedVet approved

    Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902]. … Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug

  6. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the

  7. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  8. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

    Categories: Drugs Used in Diabetes
  9. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

    Products: Malogen In Oil Liq 100mg/ml
  10. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older.

    Products: N/a, Midazolam in Sodium Chloride